Optimizing Outcomes for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Most patients diagnosed with breast cancer have a subtype that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). While this form of breast cancer is generally highly treatable in its earlier stages, some patients will unfortunately develop metastatic disease. However, the treatment landscape for HR+, HER2- metastatic breast cancer has seen significant advancements in recent years, with the introduction of new therapies that improve both quality of life and progression-free survival. These treatment options include endocrine therapies, CDK4/6 inhibitors, and antibody-drug conjugates (ADCs).

As the number of promising treatment options expands, it remains a challenge for community oncology providers to stay abreast of the latest and most effective management strategies for their patients. To address this need, the Association of Cancer Care Centers (ACCC) has launched an educational initiative to equip community oncology providers with up-to-date education and information about evidence-based practices for managing HR+, HER2- metastatic breast cancer.

Featured Resources

Best Practice Guide
Explore a concise overview of effective practices for oncology clinicians highlighting recent guideline-concordant advances in systemic therapies and best practices for biomarker testing of patients with HR+, HER2- metastatic breast cancer.
Download Now

Interactive e-Course

Optimizing Outcomes for HR+, HER2- Metastatic Breast Cancer
This program will cover evidence-based treatment options and treatment selection strategies, the management of treatment-related adverse events, and ways to optimize quality of life for patients with HR+, HER2- metastatic breast cancer. Earn up to 1.5 CE/CME hours.
Learn Now